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We previously reported the synthesis and biological activity of a series of cationic bis-indoles with potent, broad-spectrum anti-
bacterial properties. Here, we describe mechanism of action studies to test the hypothesis that these compounds bind to DNA
and that this target plays an important role in their antibacterial outcome. The results reported here indicate that the bis-indoles
bind selectively to DNA at A/T-rich sites, which is correlated with the inhibition of DNA and RNA synthesis in representative
Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) organisms. Further, exposure of E. coli and S. au-
reus to representative bis-indoles resulted in induction of the DNA damage-inducible SOS response. In addition, the bis-indoles
were found to be potent inhibitors of cell wall biosynthesis; however, they do not induce the cell wall stress stimulon in S. au-
reus, suggesting that this pathway is inhibited by an indirect mechanism. In light of these findings, the most likely basis for the
observed activities of these compounds is their ability to bind to the minor groove of DNA, resulting in the inhibition of DNA
and RNA synthesis and other secondary effects.
New therapeutic agents to treat infections caused by multi-drug-resistant (MDR) pathogens represent a critical unmet
medical need (1, 2). Toward this end, we recently reported a series
of synthetic bis-indole agents (Fig. 1) that exhibit potent antibac-
terial activity in vitro against a broad spectrum of Gram-positive
and Gram-negative pathogens (3–5). The most potent member of
this series, MBX-1162 (Fig. 1), was found to be active (MIC90
values are reported in g/ml) against methicillin-resistant Staph-
ylococcus aureus (0.06 g/ml) and S. epidermidis (0.015 g/ml),
vancomycin-resistant Enterococcus faecalis (0.015 g/ml) and E.
faecium (0.004 g/ml), Escherichia coli (0.25 g/ml), Klebsiella
pneumoniae (0.5 g/ml), Proteus mirabilis (2 g/ml), Pseudomo-
nas aeruginosa (1 g/ml) (3), Acinetobacter baumannii (2 g/ml)
(5), and multidrug-resistant Mycobacterium tuberculosis (0.05
g/ml) (6). Further testing also revealed that the bis-indoles are
active in murine models of infection, increasing significantly the
survival of mice that were infected with lethal doses of Bacillus
anthracis, S. aureus, or Yersinia pestis (4). The bis-indoles exhibit
rapid bactericidal activity against all organisms that have been
tested to date: the viability of cultures of B. anthracis, B. subtilis,
and Y. pestis were reduced by 10,000-fold in less than 4 h after
treatment with MBX-1066 at 4 the known MIC (4). In addi-
tion, the bis-indoles exhibit potent antifungal activity against
Candida albicans, C. krusei, C. glabrata, C. parapsilosis, and Cryp-
tococcus neoformans and exhibit rapid fungicidal activity against
C. albicans (7).
Given the potent antimicrobial activity of the bis-indoles, un-
derstanding the mechanism(s) of action that leads to the rapid
bactericidal activity of these compounds is of interest. Preliminary
mechanistic studies suggested that MBX-1066 selectively inhibits
DNA synthesis in B. subtilis (4). In parallel work, several attempts
to isolate mutants of S. aureuswith reduced susceptibility to MBX-
1066 (4) and MBX-1162 (unpublished data) were unsuccessful,
suggesting that the bis-indoles do not inhibit a distinct protein or
RNA target. Together, these observations raise the possibility that
the bis-indoles act through a general, nonspecific mechanism.
While the most likely nonspecific mechanism is disruption of the
membrane potential or integrity, our studies indicated that the
bis-indoles do not affect the transmembrane proton gradient or
membrane integrity of B. subtilis, suggesting that some other fun-
damental target is probably involved (4). In a recent report, we
have shown that the bis-indoles localize to the nucleus of the fun-
gal pathogen C. albicans and strongly inhibit DNA synthesis (7),
indicating that the potent antifungal activity of these compounds
is likely to be the result of their DNA binding activity. This finding
strongly suggests that the nonspecific target of the bis-indoles is
DNA. Indeed, the bis-indole compounds studied here share sev-
eral important structural and chemical features with well-estab-
lished DNA minor groove-targeted compounds, such as DAPI
(4=,6=-diamidino-2-phenylindole) (Fig. 1). These features include
“sickle-shaped,” planar structures, terminally positioned cationic
functionalities, and heteroatoms with the potential to form hy-
drogen bonds with the floor of the minor groove of B-form DNA.
To investigate the antibacterial mechanism of the bis-indoles,
we carried out studies to test the hypothesis that DNA binding
activity of these compounds plays an important role in their anti-
bacterial activity. Here, we report the results of studies that veri-
fied DNA binding in cells, determined the composition of DNA
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sequences targeted selectively by the bis-indole compounds in this
series, and evaluated their relative binding affinities to a preferred
DNA sequence. In addition, we measured the biological conse-
quences of DNA binding on macromolecular synthesis pathways
and stress response. Taken together, the results of our experiments
support the hypothesis that the primary cellular target of this se-
ries of bis-indoles is DNA. Further, these findings support a link
between the DNA binding activity of these compounds and their
cytotoxicity against mammalian cells, which limits their potential
use as antimicrobial agents.
MATERIALS AND METHODS
Bacterial strains and growth conditions. The following bacterial strains
were used in these studies: Staphylococcus aureusNCTC 8325 (8), S. aureus
RN4220 (pAmi-Rec) (9), S. aureus RN4220 (pAmi-vraX) (this study [see
below]), Escherichia coli KLE700 (WT) and KLE701 (tolC) (10),
GW1000 [F thr-1 araC14 leuB6 (argF-lac)169 tsx-33 glnV44 galK2 
sulA211 hisG4 recA441(ts) rpsL31(strR) xylA5 argE3(Oc) thi-1 ilv(ts)]
(11), GW1000 lexA3(Ind), GW1000 lexA300::spec(Def), GW1000
recA::kan, and GW1000 glmS::mini-Tn7 (PsulA-luxCDABE, FRT-gent-
FRT). To construct the SOS reporter strain GW1000 glmS::mini-Tn7
(PsulA-luxCDABE, FRT-gent-FRT), the promoter of the SOS-regulated
gene sulA was amplified using a PCR programmed with the primers PsulA-
Dra-L (ATCGCTCCCACTATGTGCGGATCCGTTAACTACGAAAA)
and PsulA-Dra-R (CATCGCTCCCACCGCGTGGCCCCTGTGAGTTA
CTGTATGG), which contain unique DraIII restriction sites (underlined)
to enable directional cloning upstream of the luxCDABE operon of Pho-
torhabdus luminescens (12), which is carried in the mini-Tn7 element of
pUC18R6K-mini-Tn7T-Gm (13). The resulting PsulA-luxCDABE re-
porter construct was transferred to a unique site (glmS) in the chromo-
some of E. coli TOP10 as previously described (13) and was transferred to
GW1000 using P1 transduction. The S. aureus reporter plasmid pAmi-
vraX was constructed as follows. The promoter of the vraX gene in S.
aureus, which is induced in response to cell wall stress (14–16), was am-
plified using PCR programmed with primers PvraX-F (AATTTGGATCC
TGATTTTGTTGGTCCTGTGG) and PvraX-R (ATTAAGTCGACACCT
CCTTTGCTACTCTATGGTT), which contain restriction sites for
BamHI and SalI (underlined), respectively. The vraX promoter fragment
was cloned into the BamHI and SalI sites of pAmi-lux (17) using standard
methods, and the recombinant plasmid was transferred to S. aureus using
electroporation. All strains were grown in tryptic soy broth (TSB) at 37°C
on a platform shaker (250 rpm). Reserpine (20 g/ml) was added to
cultures of S. aureus to inhibit efflux pump activity (18).
Chemicals. The bis-indoles used in the present study (Fig. 1) were
synthesized at Microbiotix, Inc., as described previously (19). Netropsin,
ciprofloxacin, vancomycin, sanguinarine, and DAPI were purchased from
Sigma-Aldrich (St. Louis, MO).
Visualization of bis-indoles in bacteria using fluorescence micros-
copy. An exponentially growing culture of S. aureus (OD600  0.4) was
treated with MBX-1066 at concentrations equivalent to 0, 1, and 4
the MIC for 30 min at room temperature. A culture of E. coli KLE701 was
grown in the presence of 10 M sanguinarine (Sigma-Aldrich), which
blocks cell division by inhibiting polymerization of FtsZ (20), resulting in
filamented cells. The treated cells were fixed with 0.04% glutaraldehyde
and 2.5% formaldehyde for 30 min and then stained with either MBX-
1066 at 4 the MIC or 0.3 M Syto 9 (Molecular Probes, Portland, OR)
for 30 min. After staining, the cells of S. aureus and E. coli were harvested
and resuspended in water containing 0.02% agarose, and a total of 5l of
each suspension was placed on a microscope slide, covered with a cover-
slip, and visualized under light (differential interference contrast [DIC])
and fluorescence microscopy using the DAPI and fluorescein isothiocya-
nate filter sets to visualize MBX-1066 and Syto 9, respectively.
Analyses of DNA binding. The DNA binding site selectivity of each
bis-indole compound was determined by using a fluorescence intercalator
displacement (FID) assay (21–25). The 136-member hairpin deoxyoligo-
nucleotide library required for this study contained binding sites of 4 bp
and was purchased from Trilink Biotechnologies, Inc., as individual ly-
ophilized solids. The concentrations of the hairpin oligodeoxynucleotides
were determined as described previously (21) using UV at 90°C and sin-
gle-strand extinction coefficients to ensure accurate concentration deter-
mination. All bis-indole compounds examined were initially prepared as
10 mM dimethyl sulfoxide (DMSO) stock solutions.
FID analyses were carried out using Costar black 96-well plates loaded
with sodium cacodylate buffer containing ethidium bromide (EtBr; 150
l of 6M EtBr, 120 mM NaCl, and 12 mM sodium cacodylate [pH 7.4]).
To each well was added one hairpin oligodeoxynucleotide of the library
(30 l of 10 M hairpin solution, which is equivalent to 70 M in base
pairs, dissolved in H2O). The final concentrations in each well were 1.5
M DNA-hairpin, 4.5 M EtBr, and 0.75 to 2 M DNA binding agent.
The final buffer consisted of 10 mM sodium cacodylate (pH 7.4)–100 mM
FIG 1 Chemical structures of the bis-indole compounds used in this study
compared to the DNA minor groove binding dye DAPI.
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NaCl. After incubation at 25°C for 30 min, each well was read on a Varian
Cary Eclipse fluorescence plate reader (Ex, 545 nm; Em, 595 nm). Com-
pound assessments were conducted with each well acting as its respective
control well (no agent  100% fluorescence; no DNA  0% fluores-
cence). Fluorescence readings are reported as the percent fluorescence
decrease relative to the control wells.
Titrations to determine relative binding affinities were carried out
using a 50-l quartz microcuvette loaded with sodium cacodylate buffer
(containing 100 mM NaCl and 10 mM sodium cacodylate [pH 7.4]) and
ethidium bromide (4.5 M final concentration); the total volume was 50
l. Sample fluorescence was measured on a Varian Cary Eclipse spectro-
fluorometer and normalized to 0% fluorescence. At this point, the hairpin
deoxyoligonucleotide AATT was added to a concentration of 1.5 M
(hairpin final concentration), and the resulting fluorescence was normal-
ized to 100%. Titrations were conducted by adding aliquots of agent (0.5
l aliquots of 0.15 M bis-indole in buffer) and measuring the resulting
fluorescence decrease after a 5-min equilibration time. Compound addi-
tions were continued until the system reached saturation and the fluores-
cence remained constant with subsequent additions of agent. Data pro-
vided by these titrations were analyzed through standard Scatchard
binding analyses exactly as described previously (21, 23).
Macromolecular synthesis assays. The effects of the bis-indoles and
netropsin on various macromolecular synthetic pathways in S. aureus
NRS-77 (NCTC 8325) and E. coli KLE701—DNA, RNA, protein, lipid,
and peptidoglycan synthesis—were measured as described previously
(26). Because the presence of active efflux pumps significantly decreases
the antibacterial activity of MBX-1195, the effect of efflux on the activity
of all the test compounds in the macromolecular synthesis (MMS) assay
was minimized by using an efflux-defective strain of E. coli KLE701
[tolC]) or by growing S. aureus in the presence of 20g of reserpine/ml,
an efflux pump inhibitor. Briefly, bacterial cultures were grown aerobi-
cally in Luria-Bertani (LB) medium at 37°C to midlogarithmic growth
phase (i.e., an optical density at 600 nm [OD600] of 0.1 to 0.2). The cul-
tures were added to prewarmed (37°C) 96-well assay plates that were
loaded with 50 l of LB media containing a radiolabeled precursor at
twice the final concentration and test compounds at concentrations rang-
ing from 0.16 to 16 the MIC. The radiolabeled precursors used for
each macromolecular synthetic pathway were as follows: [3H]thymidine
(DNA), [3H]uridine (RNA), [3H]leucine (protein), [3H]acetate (lipid),
and [3H]-N-acetylglucosamine (peptidoglycan). The final concentration
of DMSO in each well, including the untreated controls, was 2%. The
assay plates were incubated at 37°C for 20 min, which is less than the
doubling time of E. coli and S. aureus (40 min) under the conditions of
the assay. To terminate the assay and to precipitate macromolecules, 100
l of 20% trichloroacetic acid (TCA) was added to each well, and the assay
plates were placed on ice for 30 min. The precipitated macromolecules
were collected by filtration in 96-well MultiScreen (Millipore) filter plates
with glass fiber filters. After repeated washes with 5% TCA and then 95%
ethanol, the plates were dried, and the amount of radioactivity bound to
each filter was measured with a Perkin-Elmer MicroBeta scintillation
counter. Each compound was tested in triplicate on the same assay plate,
each data point represents the average of three replicates, and the error
bars represent the standard deviations. The concentration that inhibited
each macromolecular synthetic pathway by 50% (IC50) was determined
using the four-parameter nonlinear curve-fitting function of GraphPad
Prism (GraphPad Software). To monitor assay specificity, the following
pathway-specific antibiotics were included in each assay: ciprofloxacin
(DNA), rifampin (RNA), ampicillin (cell wall-E. coli), vancomycin (cell
wall-S. aureus), irgasan (lipid), and chloramphenicol (protein).
Antibacterial activity assays. The MIC of antibacterial agents and
biocides were determined using the broth microdilution method essen-
tially as described in Clinical and Laboratory Standards Institute protocol
M7-A7 (27), except that LB medium was used instead of Mueller-Hinton
broth. Serial 2-fold dilutions of test compounds were made in DMSO at
concentrations 50-fold higher than the final concentration: the diluted
compounds were added to the assay plates, and 100 l of the inocula was
added to each well. The final concentration of DMSO in each assay was
2%. To determine the effect of serum on the antibacterial activity of the
bis-indoles, 10% fetal bovine serum (FBS; Gibco) was added to the growth
medium at a final concentration of 10%.
Killing curve assays were performed essentially as described previously
(28). Exponential bacterial cultures grown in LB medium were diluted to
a cell density of 107 in LB medium, followed by the addition of MBX-
1162 to a minimally bactericidal concentration (0.06 g/ml). Viability
was monitored over 4 h by removing samples, making serial dilutions in
saline, and spotting 5 l of each dilution onto the surface of an LB agar
plate in triplicate. Colonies were counted after the plates were incubated at
37°C for 16 to 18 h, the CFU per ml were calculated, and the averages and
standard deviations for the three replicates were determined. Each exper-
iment was repeated at least three times, and the results from a represen-
tative experiment are shown.
Cytotoxicity versusmammalian (HeLa) cells.The cytotoxicity of test
compounds against HeLa cells (ATCC CCL-2) was determined as de-
scribed previously (29). Briefly, each well of a 96-well plate was seeded
with 4,000 cells of HeLa cells in 200 l of minimum essential medium
containing 1 Earle’s salts, 1.5 g/liter sodium bicarbonate (GE Health-
care), and 10% FBS. After the cells attached (2 to 4 h), 2 l of various
concentrations (2-fold dilution series) of compounds dissolved in DMSO
were added to the media, and the plates were incubated at 37°C in a 5%
CO2 atmosphere for 3 days. The cell viability in each well was measured
using the redox sensitive dye MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyltetrazolium bromide]. The absorbance of each well was plotted as a
fraction of the untreated versus drug concentration, and the concentra-
tion that produces 50% cytotoxicity (CC50) was determined using the
four-parameter nonlinear curve-fitting function of GraphPad Prism
(GraphPad Software).
Cell-based reporter assays. For SOS cell-based reporter assays, E. coli
GW1000 glmS::mini-Tn7 (PsulA-luxCDABE, FRT-gent-FRT) or S. aureus
RN4220 (pAmi-Rec) were grown to mid-log phase (OD600 0.2) in tryp-
tic soy broth at 37°C, and 100 l was transferred to each well of a 96-well
microassay plate (Costar 3915) containing various amounts of a bis-in-
dole or netropsin (0.125 to 4 the MIC). Ciprofloxacin (CIP) was used
as a positive control at a concentration of 5 the MIC (0.1 g/ml) for E.
coli and 2 the MIC (2 g/ml) for S. aureus. Each condition was repli-
cated in a total of eight separate assay wells (one column on the assay
plate). The assay plate was placed in a Victor3 V, and light emission was
monitored over time at 37°C. The average values and standard deviations
for the eight replicates were calculated. The fold induction for each treat-
ment compared to the untreated control has been plotted as a function of
time. The procedure described above was also used for the cell wall stress
stimulon reporter assays, except that S. aureus RN4220 (pAmi-vraX) was
used as the reporter strain and vancomycin at a concentration of 2 the
MIC (4 g/ml) was used as the positive control.
RESULTS AND DISCUSSION
Biological activities of thebis-indoles.The antibacterial activities
(MIC) and mammalian cell cytotoxicities (CC50) of the bis-in-
doles (see Fig. 1) used in this study are shown in Table 1. The
bis-indoles exhibit potent antibacterial activity against S. aureus
and E. coli. In addition, the bis-indoles are rapidly bactericidal
against S. aureus and E. coli. As shown in Fig. 2, MBX-1162 (4
the MIC) reduced the numbers of viable cells by 5 logs within 2 h.
The antibacterial activity of the bis-indoles was not affected by the
presence of 10% FBS or efflux, with the exception of MBX-1195,
which had no measureable activity against efflux proficient organ-
isms. To compare directly the activities of the bis-indoles, we per-
formed all assays using an efflux-defective strain ofE. coli (KLE701
[tolC]) or S. aureus treated with inhibitor of efflux (20 g of
reserpine/ml).
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In vitro and in situ DNA binding assays. The structural sim-
ilarities shared by the bis-indoles and DAPI (Fig. 1), a well-estab-
lished dye that fluoresces strongly when bound to the minor
groove of A/T-rich double-stranded DNA (ex 358 nm; em
461 nm), suggest that the bis-indoles may target and bind to DNA.
To test this possibility, the fluorescence of a representative bis-
indole, MBX-1066, was examined in the presence or absence of
Bacillus anthracis genomic dsDNA. Samples containing a fixed
concentration of this DNA (4g/ml, equivalent to 3M bp) were
combined with various amounts of MBX-1066 and monitored for
changes in fluorescence intensity (ex 390 nm, em 460 nm).
As shown in Fig. 3A, the fluorescence intensity of the sample in-
creased steadily upon the addition of MBX-1066 up to 6M total
MBX-1066 representing a 2:1 bis-indole/DNA base-pair ratio.
The fluorescence decreases observed with additions of compound
beyond the 2:1 point of charge neutralization were most likely due
to precipitation of the DNA. In comparison, the fluorescence of
samples containing MBX-1066 alone (no DNA) did not change
over the same concentration range. These results clearly indicate
that MBX-1066 binds to DNA in vitro and does so in a manner that
results in increased bis-indole fluorescence. Taken together, the
evidence indicates that the bis-indoles bind to DNA in vitro.
To verify that MBX-1066 can bind to DNA within intact bac-
terial cells, exponentially growing cultures of S. aureus NCTC
8325 were treated with 0.5 g/ml MBX-1066 (4 the MIC) and
viewed via light and fluorescence microscopy using a DAPI filter.
As shown in Fig. 3B, cells treated with MBX-1066 were fluores-
cent, but untreated cells were not, suggesting that MBX-1066
binds to the genomic DNA present in living cells of S. aureus. To
confirm that the MBX-1066-derived fluorescence colocalized
with bacterial genomic DNA, filamented E. coli cells were pro-
duced by growth in the presence of sanguinarine, treated with
MBX-1066 or the DNA intercalating dye Syto9, and then exam-
ined using light and fluorescence microscopy. Sanguinarine treat-
ment, as expected, resulted in filamentous cells with multiple, dis-
crete nucleoids containing genomic DNA. As shown (Fig. 3C), the
filaments contained discrete nucleoids that exhibited colocalized
Syto9 and MBX-1066 fluorescence, verifying that MBX-1066 can
target and bind genomic DNA in intact bacterial cells.
Examination ofDNAbinding sequence selectivity. The DNA
binding activities of the bis-indoles were assessed in greater detail
using a standard FID assay that can identify preferred sites of
drug-DNA binding and their rank order (21–25). In brief, the FID
assay measures the ability of a compound to displace a fluorescent
DNA intercalating agent (ethidium bromide) that is bound to
double-stranded DNA; binding competition results in decreased
fluorescence. To identify the preferred binding sites of these com-
pounds, we used the FID assay to screen libraries of synthetic
hairpin oligonucleotides containing all possible 4- or 5-bp dou-
ble-stranded DNA binding sites (136 or 512 individual DNA oli-
gonucleotides, respectively). The relative fluorescence decreases
for each oligonucleotide were rank ordered and displayed in the
form of a histogram to visualize the DNA sequences of preferred
binding and to compare the selectivity of DNA binding among
this series of compounds. The histograms for MBX-1066 and
MBX-1162 are shown in Fig. 4A and B, respectively. The histo-
grams illustrate that both compounds bind preferentially to se-
quences composed exclusively of A/T base pairs and that MBX-
1162 produced greater decreases in fluorescence than MBX-1066,
indicating a higher DNA binding affinity. In comparison, MBX-
1196 displayed an FID histogram profile that was qualitatively
most similar to MBX-1162, while MBX-1195 was similar to MBX-
1066; MBX-1090 displayed a profile that was intermediate be-
tween these two extremes (see Fig. S1 in the supplemental mate-
rial).
Further examination of the top sequences selected by each of
the bis-indoles identified the nucleotide compositions of pre-
ferred sequences to be 5=-AATT and 5=-AAAT. To assess the rela-
tive affinities of the bis-indoles for the preferred binding site
TABLE 1 Antibacterial activity and cytotoxicity values for various compoundsa
Organism Strain Effluxb % FBS
MIC (g/ml)c
MBX-1066 MBX-1090 MBX-1162 MBX-1195 MBX-1196 CIP NET
S. aureus NRS-77 	 0 0.062 1 0.062 32 0.12 0.12
– 0 0.062 0.5 0.062 1 0.12 0.12 16
– 10 0.062 0.5 0.062 1 0.12 0.062
E. coli KLE700 	 0 0.5 2 0.5 32 0.5 0.016
KLE701 – 0 0.25 0.5 0.25 4 0.5 0.002 16
KLE701 – 10 0.25 0.5 0.25 2 0.25 0.002
HeLa cells (CC50 [g/ml]) 10 32.5 10 4 15 15 ND ND
a FBS, fetal bovine serum; CIP, ciprofloxacin; NET, netropsin; ND, not determined; CC50, concentration that produces 50% cytotoxicity.
b	, efflux proficient;, efflux deficient.
c Note that the bottom row of data show CC50 (g/ml) values.
FIG 2 MBX-1162 is rapidly bactericidal against E. coli KLE700 and S. aureus
NRS-77 at a concentration equivalent to 4 the MIC.
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AATT, quantitative titrations of each compound were tested in
the FID assay, and the results were subjected to Scatchard analyses
to estimate the binding affinity (Ka). The relative affinities of the
bis-indoles for 5=-AATT were as follows: MBX-1162 (Ka  31
106 M1)
MBX-1196 (Ka 1 10
6 M1)
MBX-1066 (Ka




1195 (Ka not determined, as it was too weak). These values indi-
cated that the binding affinity of the most potent bis-indole
(MBX-1162) to AATT is closest to that displayed by netropsin
(65  106 M1) when measured by similar experimental means
(21, 23); the remaining compounds are best classified as moderate
or relatively weak DNA binding agents. Importantly, in common
with many other A/T-targeted agents, the bis-indoles display a
preference for AATT sites. Previous studies have shown that
FIG 3 The increased fluorescence of MBX-1066 in the presence of DNA and in bacterial cells is consistent with DNA binding. (A) Fluorescence enhancement
of MBX-1066 in the presence of genomic DNA. The fluorescence (RFU) of various concentrations of MBX-1066 in the presence of Bacillus anthracis genomic
DNA (6 M nucleotides) was measured as the emission at 460 nm after excitation with 390 nm. (B) MBX-1066 fluorescence in bacterial cells is consistent with
selective DNA binding. Living cells of S. aureus NCTC 8325 were exposed to 0.5g of MBX-1066/ml and viewed under light and fluorescence microscopy using
a DAPI filter. (C) MBX-1066 fluorescence is colocalized to nucleoids in fixed cells of E. coli. A culture of E. coli 701 (tolC) was grown in the presence of the cell
division inhibitor sanguinarine (10M). The cells were fixed and stained with MBX-1066 (1 the MIC) and the DNA intercalating dye Syto9 and viewed under
light (DIC) and fluorescence microscopy using DAPI and green fluorescent protein filters to visualize MBX-1066 and Syto9, respectively.
FIG 4 Merged-bar histograms resulting from FID analyses of compounds MBX-1066 (A) and MBX-1162 (B). Each compound was analyzed at 0.75, 1.5, and 2.0
M concentrations; the results for the 2.0 M analyses are color-coded as follows: red, G/C-only 4-bp oligonucleotide cassettes; blue, A/T-only 4-bp cassettes;
and black, mixed sequence cassettes. The sequences of the top 15 rank-ordered oligonucleotides are shown in each plot expansion. The highest ranking binding
sequence for both MBX-1066 and MBX-1162 was 5=-AATT.
DNA-Targeted Antibacterial Bis-Indoles
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AATT sites are conducive to minor groove binding due to the
characteristic width and depth of the minor groove (30, 31). Col-
lectively, the observations described above support the notion that
the MBX bis-indoles target the DNA minor groove and, like other
synthetic minor groove binders (32–34), display a range of DNA
binding affinities influenced by their structural differences (e.g.,
the nature of the central linker, the extent of the overall compound
curvature, and substituent sizes).
Effects of DNA binding on MMS. To examine the effect of
DNA binding on the physiology of bacterial cells, we measured the
dose-dependent effects of MBX-1066, MBX-1162, and MBX-1195
on each of the major bacterial macromolecular synthetic (MMS)
pathways inE. coli and S. aureus. The assay was terminated after 20
min of exposure, which is less than the doubling time of40 min
for both organisms in the assay. The resulting dose-response
curves were analyzed with a four-parameter curve-fitting algo-
rithm to calculate the half-maximal inhibitory concentrations
(IC50s) for each compound against each of the MMS pathways,
which provides a quantitative measurement for the inhibitory ac-
tivities of a compound against each pathway. Netropsin, an anti-
bacterial compound known to bind to the minor groove of DNA
(35), was used as a control in the experiment. Representative dose-
response curves are shown in Fig. 5, and the IC50s of each com-
pound for each of the MMS pathways in E. coli and S. aureus are
shown in Table 2. In contrast to our previous results (4), which
showed that MBX-1066 inhibits DNA synthesis in B. subtilis, the
results from this more sensitive assay protocol show that the two
bis-indoles that bind to DNA with a high affinity (MBX-1066 and
MBX-1162) inhibited all of the MMS pathways in S. aureus and E.
coli at relatively low concentrations but were most active against
RNA, DNA, and cell wall synthesis. The control compound ne-
tropsin was most active against RNA synthesis in S. aureus and
against DNA and RNA synthesis in E. coli. In contrast, MBX-1195
(undetectable affinity for DNA) inhibited RNA and cell wall syn-
thesis in S. aureus and inhibited all pathways at relatively high
concentrations in E. coli (Table 2). The results of these studies
indicate that the effects of the DNA binding bis-indoles com-
pounds on bacterial physiology is more complicated than was in-
dicated by our previous results using B. subtilis alone (4), possibly
due to differences between bacterial species, assay conditions, and
efflux pump activity. We think that the current results accurately
portray the mechanisms of action of the bis-indoles, since it is
unlikely that the DNA binding activity of these compounds alone
could account for their rapid bactericidal activity.
Despite the issues noted above, the current findings showing
that MBX-1066 and MBX-1162 are most potent against DNA and
RNA synthesis are consistent with the outcomes of studies of an-
other series of DNA binding antibacterial agents (36). The potent
inhibition of DNA and RNA synthesis observed in our studies is
most likely to be the consequence of the DNA binding activity of
FIG 5 Representative MMS assays indicate bis-indoles primarily inhibit DNA, RNA, and cell wall biosynthesis in S. aureus and E. coli. (A) E. coli KLE701 treated
with MBX-1066; (B) S. aureus NRS-77 treated with MBX-1066.




DNA RNA Protein Cell wall Lipid
S. aureus MBX-1066 0.53 0.14 0.18 0.01 3.96 0.97 0.29 0.03 44.4 16
NRS-77 MBX-1162 0.10 0.02 0.06 0.01 0.99 0.42 0.09 0.002 4.31 1.1
NRS-77	 reserpine MBX-1195 16 4.7 2 16 9.8 4.3 16
NET 149.4 31.4 48.6 12.4 256 139.6 38.2 256
E. coli KLE701 (tolC) MBX-1066 3.39 0.5 1.37 0.14 16 0.64 0.06 16
MBX-1162 0.12 0.02 0.08 0.002 0.25 0.02 0.06 0.006 0.85 0.36
MBX-1195 10.2 3.8 14.1 5.3 37.7 10.4 21.6 17.3 22.4 9.7
NET 53.5 7.2 40.7 4.7 256 256 120.5 25.8
a NET, netropsin.
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these compounds and actually parallels the relative DNA binding
affinities of these compounds (see above). Compounds bound to
the minor groove of DNA increase the stability of the double helix,
which affects the activity of both DNA and RNA polymerases. The
affinity of a compound for the minor groove is directly correlated
with increased Tm of dsDNA (higher DNA affinity compounds
results in higher Tm), which results in greater inhibition of DNA
and RNA synthesis. In addition, minor groove binders change the
structure of dsDNA, which could sterically block the binding of
proteins involved in DNA replication and transcription. There-
fore, it is likely that the DNA binding activity of the bis-indoles is
a major component of the mechanism of action of these com-
pounds. The proposed mechanism for the bis-indoles is thus con-
sistent with that of other classes of DNA binding antibacterial
agents (37).
While the inhibition of DNA and RNA synthesis constitutes a
well-established cellular consequence of treatment with a DNA
binding agent, the potent inhibition of the other MMS pathways,
particularly cell wall synthesis, suggests that there may be addi-
tional mechanisms of action, or that the inhibition of cell wall
synthesis is a secondary effect. The most likely mechanism that
would affect all MMS pathways is membrane disruption; however,
we have shown previously that the bis-indoles do not perturb the
transmembrane proton gradient (4). Therefore, additional cellu-
lar targets for the action of the bis-indoles, if they indeed exist,
have yet to be identified. To determine whether these compounds
act directly on the cell wall synthetic pathway, we measured the
effect of the bis-indoles and netropsin on a strain of S. aureus
carrying a reporter construct that produces a bioluminescent sig-
nal in response to inhibitors of cell wall synthesis. The reporter
construct consists of the promoter of vraX, which is induced by
inhibitors of cell wall and teichoic acid synthesis and is part of the
cell wall stress stimulon [CWSS] (15, 16, 38), that has been fused
to a bacterial luciferase operon (luxABCDE) carried on plasmid
(pAmi-vraX). As shown in Fig. 6E to H, exposure of the cell wall
stress reporter strain to MBX-1066 (Fig. 6E), MBX-1162 (Fig. 6F),
and netropsin (Fig. 6H) did not result in significant biolumines-
cence, even when concentrations of the compounds were 4 the
MIC, indicating that these compounds do not inhibit cell wall
synthesis directly. Therefore, it is likely that these compounds in-
hibit cell wall biosynthesis in the MMS assay through an uniden-
tified, indirect mechanism. For example, the bis-indoles could
inhibit uptake of the radiolabeled cell wall precursor (N-acetylg-
lucosamine). In contrast, exposure to MBX-1195 (Fig. 6G) re-
sulted in significant levels of bioluminescence, indicating that the
compound inhibits cell wall or teichoic acid synthesis; however,
the level of inhibition was significantly lower than that of the
positive control VAN. Therefore, MBX-1195 appears to work
through a different mechanism of action than the bis-indoles that
have higher affinities for DNA. For example, MBX-1195 may in-
duce the cell wall stress stimulon by modifying the properties of
the cell membrane without perturbing the transmembrane proton
gradient, as is the case with daptomycin (39). Further experiments
are required to identify the putative target of MBX-1195 in the cell
wall biosynthetic pathway.
Bis-indoles induce the SOS response. The DNA binding ac-
tivity of the bis-indoles raised the possibility that an interaction
between these compounds and DNA might result in induction of
FIG 6 Bis-indoles induce the DNA damage-inducible SOS response, but not the cell wall stress stimulon, in S. aureus. (A to D) An S. aureus strain carrying an
SOS-inducible reporter construct, consisting of the recA promoter fused to an operon encoding bacterial luciferase (luxABCDE) on pAmi-Rec (17), was treated
with various concentrations of MBX-1066 (A), MBX-1162 (B), MBX-1195 (C), or netropsin (D), and the light emission was monitored over time. Concentra-
tions are expressed as multiples of the MIC (see Table 1). Ciprofloxacin (CIP), an inhibitor of DNA replication, and vancomycin (VAN), an inhibitor of cell wall
synthesis, were used as positive and negative controls, respectively. (E to H) An S. aureus strain carrying a cell wall stress-inducible reporter construct, consisting
of the vraX promoter fused to an operon encoding bacterial luciferase (luxABCDE) carried on pAmi-vraX, was treated with various concentrations of MBX-1066
(E), MBX-1162 (F), MBX-1195 (G), or netropsin (H), and the light emission was monitored over time. Vancomycin (VAN) and ciprofloxacin (CIP) were used
as positive and negative controls, respectively. Each point on the graph is the average of eight replicates, and the error bars indicate the standard deviations.
DNA-Targeted Antibacterial Bis-Indoles
December 2016 Volume 60 Number 12 aac.asm.org 7073Antimicrobial Agents and Chemotherapy
the SOS response, a stress response that is induced by the presence
of single-stranded DNA resulting from DNA damage (40), or cer-
tain conditions that inhibit DNA replication (41–43). To examine
this possibility, we measured the induction of the SOS response in
E. coli and S. aureus cells that were exposed to bis-indoles. Induc-
tion of the SOS response was measured using a reporter strains of
E. coli [GW1000 glmS::mini-Tn7 PsulA-luxCDABE] and S. aureus
[RN4220 pAmi-Rec (17)] that carry reporter constructs consist-
ing of an SOS-inducible promoter fused to the luciferase operon
(luxCDABE) of Photorhabdus luminescens. DNA damage in the
reporter strain induces the SOS response, resulting in increased
expression of the luciferase operon. Ciprofloxacin (CIP), a fluo-
roquinolone antibiotic agent that induces the SOS response, was
used as a positive control. The results for the E. coli reporter strain,
shown in Fig. 7A and B, demonstrate that exposure to the higher
DNA affinity compounds MBX-1066 (Fig. 7A) and MBX-1162
(Fig. 7B) resulted in induction of the SOS response to levels com-
parable to positive control, whereas the weakest DNA binding
bis-indole, MBX-1195, did not induce the SOS response. In com-
parison, the lower levels of SOS induction produced at higher
concentrations of MBX-1162 are likely due to the rapid bacteri-
cidal activity of this compound at concentrations above the MIC
(4); this is also likely to be the explanation for the failure of ne-
tropsin to induce the SOS response in this assay. The bis-indoles
also induced the SOS response in S. aureus (Fig. 6A to C); however,
the levels of induction were lower than that of the positive control.
In addition, MBX-1066 (Fig. 6A) and MBX-1162 (Fig. 6B) in-
duced the SOS response to a lower level than did MBX-1195 (Fig.
6C) and netropsin (Fig. 6D). These data indicate that bis-indoles
induce the SOS response in both E. coli and S. aureus; however, the
effects of each compound and the overall level of SOS induc-
tion varied between the two organisms. There are several pos-
sible explanations for the observed differences. For example,
the SOS regulon of S. aureus is much more limited than that of
E. coli (44), which could decrease the range of DNA damage
signals to which the SOS regulon of S. aureus responds. In ad-
dition, the replicative DNA polymerases in S. aureus (PolC) and
E. coli (DnaE) are significantly different in primary amino acid
sequence (20% identity) (45), domain arrangements, the
presence of an intrinsic 3=–5= proofreading exonuclease do-
main in PolC (but not DnaE), and differential sensitivity to
inhibition by nucleotide analogs (46).
If bis-indole exposure results in DNA damage, then SOS-de-
fective mutants should exhibit increased sensitivity to the bis-in-
dole compounds compared to the wild type (WT). Indeed, the
MICs for MBX-1066 and MBX-1162 against isogenic recA and
lexA3(Ind) strains were consistently 2-fold lower than WT (Ta-
ble 3). In addition, we performed a time-kill assay with E. coli
FIG 7 Bis-indoles induce the DNA damage-inducible SOS response in E. coli. (A) An E. coli strain carrying an SOS-inducible reporter construct consisting of the
sulA promoter fused to an operon encoding bacterial luciferase (luxCDABE) was treated with various concentrations of MBX-1066 (A), MBX-1162 (B),
MBX-1195 (C), or netropsin (D), and light emission was monitored over time. Compound concentrations are expressed as multiples of the MIC (see Table 1).
Ciprofloxacin (CIP) at a concentration of 0.1 g/ml (5 the MIC) was used as a positive control. Each point on the graph is the average of eight replicates, and
the error bars indicate the standard deviations. (E) A RecA-defective mutant of E. coli AB1157 is more sensitive to MBX-1162 (0.016 g/ml, 0.25 the MIC for
WT) than is WT. Each point on the graph is the average of three replicates, and the error bars indicate the standard deviations.
TABLE 3 MICs for bis-indoles against wild-type and SOS-defective




Wild type (AB1157) 1 0.5 0.016
recA mutant 0.5 0.25 0.002
lexA3 (Ind) mutant 0.5 0.25 0.004
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AB1157 (WT) and recA and lexA3(Ind) mutants that were
treated with MBX-1162 at a concentration that is minimally bac-
tericidal against the WT (0.016g/ml, 0.25 the MIC). As shown
in Fig. 7E, a 0.016-g/ml concentration of MBX-1162 did not
decrease the viability of the WT or the lexA3 (Ind) strains, but it
reduced the viability of the recA strain by 100-fold over 4 h.
These results indicate that the recombination-repair activity and
not the SOS-regulatory function of RecA is required for coping
with the effects of bis-indoles. The recombination-repair activity
of RecA is required for DNA strand break repair (40), suggesting
that bis-indole exposure causes DNA strand breaks. While the
data presented above do not directly demonstrate the presence of
DNA lesions after bis-indole exposure, induction of the SOS re-
sponse in E. coli and S. aureus is indicative of DNA damage. Due to
the chemical properties of the bis-indoles, it is unlikely that these
compounds react with DNA to covalently modify the DNA. How-
ever, it is possible that the bis-indoles bound to the DNA minor
groove block the progression of the DNA replication machinery
and replication is initiated further downstream, resulting in sin-
gle-stranded DNA. Alternatively, minor groove binding com-
pounds, such as Hoechst 33342, have been shown to inhibit hu-
man topoisomerase I and trap the human topoisomerase I
cleavage complex (47), which is the basis for the antitumor activity
of these compounds. Although only speculation at this point, it is
possible that the bis-indoles interfere with the activity of a bacte-
rial topoisomerase I or II enzyme, resulting in single- or double-
stranded DNA breaks. Further experiments are needed to deter-
mine the exact nature of the DNA damage produced by the bis-
indoles.
The preceding studies indicate that the bis-indole series of
compounds under investigation here target and bind to double-
stranded DNA in vitro and within bacterial cells. These agents
display a distinct preference for A/T-rich DNA and behave in a
fashion quite reminiscent of structurally similar compounds such
as DAPI, netropsin, and the clinically used diamidine, pentami-
dine. Indeed, the bis-indoles described here are very similar to
pentamidine and other DNA-targeted diamidine derivatives in
that these compounds can enter cells, target and bind to genomic
DNA, and lead to the inhibition of DNA and RNA biosynthesis. In
further analogy to the bis-indoles described here, diamidines such
as pentamidine are also thought to target genomic DNA in con-
junction with disruptions of other biological processes (48). Over-
all, these observations support the notion that the bis-indoles
most likely bind to the DNA minor groove as a primary target and
in doing so inhibit RNA and DNA biosynthesis. In addition, the
bis-indoles induce the SOS response in E. coli and S. aureus, sug-
gesting that exposure to these compounds results in single-
stranded DNA (the SOS inducing signal) through at least two
possible mechanisms: (i) the inhibition of DNA polymerase or
(ii) the production of DNA damage. In parallel, the bis-indoles
most likely inhibit other macromolecular synthetic pathways
through an indirect mechanism(s). Because the proposed
mechanism of action of antibacterial activity is similar to the
mechanism of antifungal activity (7), it is likely that the DNA
binding activity of the bis-indoles is responsible for the cyto-
toxicity of this class of compounds against mammalian cell
lines, which precludes their potential use as a systemic or top-
ical therapeutic agent in humans.
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